References
- Nowak MA. Evolutionary dynamics 2006; Cambridge Belknap/Harvard
- Kunkel TA, Bebenek K. DNA replication fidelity. Ann Rev Biochem 2000; 69:497 - 529
- Ramel C. Pollution, carcinogenesis and cancer prevention. Acta Oncol 1991; 30:27 - 33
- Hennings H, Glick AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, et al. Critical aspects of initiation, promotion and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med 1993; 202:1 - 8
- Kimura M. Preponderance of synonymous changes as evidence for the neutral theory of molecular evolution. Nature 1977; 267:275 - 276
- Bodmer W, Bielas JH, Beckman RA. Genetic instability is not a requirement for tumor development. Cancer Res 2008; 68:3558 - 3560
- Tomlinson I, Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med 1999; 5:11 - 12
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57 - 70
- Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789 - 799
- Cairns J. Mutation selection and the natural history of cancer. Nature 1975; 255:197 - 200
- Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, et al. Genetic progression and the waiting time to cancer. PLoS Comput Biol 2007; 3:225
- Hobbs JR. Growth rates and responses to treatment in human myelomatosis. Br J Haematol 1969; 16:607 - 617
- Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 2006; 103:18238 - 18242
- Luzzatto L, Frassoni F, Melo JV. Imatinib: can one outwit chronic myeloid leukemia?. Haematologica 2002; 87:898 - 901
- Luzzatto L, Melo JV. Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells. Blood 2002; 100:1105
- Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 2008; 112:1931 - 1941
- Blagosklonny MV. STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’. Leukemia 2002; 16:570 - 572
- Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571 and they can pre-exist to the onset of treatment. Blood 2002; 100:1014 - 1018
- Dingli D, Pacheco JM, Traulsen A. Multiple mutant clones in blood rarely coexist. Phys Rev 2008; 77:021915
- French JD, Tschumper RC, Jelinek DF. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach. Leukemia 2002; 16:1189 - 1196
- Jelinek DF, Witzig TE, Arendt BK. A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 1997; 159:487 - 496
- Jelinek DF. Mechanisms of myeloma cell growth control. Hematol Oncol Clin North Am 1999; 13:1145 - 1157
- Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10:866 - 876
- Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003; 78:106 - 113
- Tomlinson IP, Bodmer WF. Modelling the consequences of interactions between tumour cells. British journal of cancer 1997; 75:157 - 160
- Tomlinson IP. Game-theory models of interactions between tumour cells. Eur J Cancer 1997; 33:1495 - 1500
- Dingli D, Chalub FA, Santos FC, Van Segbroeck S, Pacheco JM. Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells. Br J Cancer 2009; 101:1130 - 1136
- Offord C, Bajzer Z. A hybrid global optimization algorithm involving simplex and inductive search. Lecture Notes Comput Sci 2006; 2074:680 - 688